Plautz GE - Search Results

1

Mechanism of third signals provided by IL-12 and OX-40R ligation in eliciting therapeutic immunity following dendritic-tumor fusion vaccination.

Kuriyama H, Watanabe S, Kjaergaard J, Tamai H, Zheng R, Weinberg AD, Hu HM, Cohen PA, Plautz GE, Shu S. Kuriyama H, et al. Among authors: plautz ge. Cell Immunol. 2006 Sep;243(1):30-40. doi: 10.1016/j.cellimm.2006.11.002. Epub 2007 Jan 17. Cell Immunol. 2006. PMID: 17207783

2

Memory T cells originate from adoptively transferred effectors and reconstituting host cells after sequential lymphodepletion and adoptive immunotherapy.

Wang LX, Kjaergaard J, Cohen PA, Shu S, Plautz GE. Wang LX, et al. Among authors: plautz ge. J Immunol. 2004 Mar 15;172(6):3462-8. doi: 10.4049/jimmunol.172.6.3462. J Immunol. 2004. PMID: 15004146

3

Active immunotherapy for advanced intracranial murine tumors by using dendritic cell-tumor cell fusion vaccines.

Kjaergaard J, Wang LX, Kuriyama H, Shu S, Plautz GE. Kjaergaard J, et al. Among authors: plautz ge. J Neurosurg. 2005 Jul;103(1):156-64. doi: 10.3171/jns.2005.103.1.0156. J Neurosurg. 2005. PMID: 16121986

4

Defining the synergistic effects of irradiation and T-cell immunotherapy for murine intracranial tumors.

Plautz GE, Inoue M, Shu S. Plautz GE, et al. Cell Immunol. 1996 Aug 1;171(2):277-84. doi: 10.1006/cimm.1996.0204. Cell Immunol. 1996. PMID: 8806798

5

Critical role of CD11a (LFA-1) in therapeutic efficacy of systemically transferred antitumor effector T cells.

Mukai S, Kagamu H, Shu S, Plautz GE. Mukai S, et al. Among authors: plautz ge. Cell Immunol. 1999 Mar 15;192(2):122-32. doi: 10.1006/cimm.1998.1439. Cell Immunol. 1999. PMID: 10087180

6

Tumor-induced L-selectinhigh suppressor T cells mediate potent effector T cell blockade and cause failure of otherwise curative adoptive immunotherapy.

Peng L, Kjaergäard J, Plautz GE, Awad M, Drazba JA, Shu S, Cohen PA. Peng L, et al. Among authors: plautz ge. J Immunol. 2002 Nov 1;169(9):4811-21. doi: 10.4049/jimmunol.169.9.4811. J Immunol. 2002. PMID: 12391191

7

Considerations on clinical use of T cell immunotherapy for cancer.

Plautz GE, Cohen PA, Shu S. Plautz GE, et al. Arch Immunol Ther Exp (Warsz). 2003;51(4):245-57. Arch Immunol Ther Exp (Warsz). 2003. PMID: 12956434 Review.

8

Host lymphodepletion augments T cell adoptive immunotherapy through enhanced intratumoral proliferation of effector cells.

Wang LX, Shu S, Plautz GE. Wang LX, et al. Among authors: plautz ge. Cancer Res. 2005 Oct 15;65(20):9547-54. doi: 10.1158/0008-5472.CAN-05-1175. Cancer Res. 2005. PMID: 16230420

9

Adoptive transfer of tumor-primed, in vitro-activated, CD4+ T effector cells (TEs) combined with CD8+ TEs provides intratumoral TE proliferation and synergistic antitumor response.

Wang LX, Shu S, Disis ML, Plautz GE. Wang LX, et al. Among authors: plautz ge. Blood. 2007 Jun 1;109(11):4865-76. doi: 10.1182/blood-2006-09-045245. Epub 2007 Feb 6. Blood. 2007. PMID: 17284532 Free PMC article.

10

Treatment of intracranial tumors by systemic transfer of superantigen-activated tumor-draining lymph node T cells.

Inoue M, Plautz GE, Shu S. Inoue M, et al. Among authors: plautz ge. Cancer Res. 1996 Oct 15;56(20):4702-8. Cancer Res. 1996. PMID: 8840987

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

57 results

Search Page

Filters